Special situations, growth at reasonable price, value, micro-cap

United Therapeutics: A Low P/E Biotech With Potential For Further Rapid Growth

Background: A year ago, United Therapeutics (NASDAQ:UTHR) came out with a strong quarterly earnings report, and I wrote a bullish article on it titled United Therapeutics - A Low PE, Fast-Growing Biotech Stock.

Since then, the stock has appreciated almost 30%.

UTHR has risen 20% annually on average as a public company. However, it gets little attention.

The combination of a successful biopharmaceutical company, strong stock price performance over fifteen years, relatively little publicity and a low P/E has led me to be long this name.

This article explores UTHR and propounds a generally positive investment thesis for patient investors, though risks are present.

Introduction: United Therapeutics was founded by the current CEO to find...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details